Physician profile
Prashant S Kedia
NPI 1235331661
$30,695.22
in general payments reported to CMS, 2019-2025
32 companies · $7,880 in 2025
The $7,880 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,827 · 2020: $1,995 · 2021: $3,131 · 2022: $9,829 · 2023: $3,200 · 2024: $833 · 2025: $7,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,665 · Food and Beverage: $3,445 · Consulting Fee: $1,600 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,665.00 |
| Food and Beverage | $3,444.75 |
| Consulting Fee | $1,600.00 |
| Education | $203.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19,670.86 | 2019-2025 | Resolution 360 Clip, General - Therapies, Exalt Model D |
| Olympus Corporation of The Americas | $2,607.60 | 2019-2024 | Single Use Aspiration Needle Na-U200h |
| Olympus Corporation | $1,802.50 | 2019-2020 | |
| Olympus Medical Systems Corporation | $1,100.00 | 2025 | |
| Medtronic, INC. | $948.53 | 2021-2024 | Endoflip, Prodigi, Nexpowder |
| Abbvie INC. | $919.15 | 2020-2025 | |
| Covidien LP | $727.00 | 2020 | |
| Erbe USA INC | $672.58 | 2019-2022 | |
| Pentax of America, INC. | $429.40 | 2022-2025 | Pentax Medical, C2 Cryoballoon Focal Controller, C2 Cryoballoon |
| Lumendi LLC | $340.74 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $251.08 | 2022-2023 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $191.09 | 2024-2025 | |
| Apollo Endosurgery US INC | $170.18 | 2019-2022 | |
| Olympus America INC. | $158.23 | 2024-2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Steris Corporation | $141.73 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $135.73 | 2025 | Eyemax |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.85 | 2019-2025 | Xifaxan |
| Celgene Corporation | $49.38 | 2023 | Zeposia |
| Amgen INC. | $38.93 | 2025 | Uplizna |
| Merck Sharp & Dohme LLC | $36.98 | 2022-2023 | Dificid |
| Redhill Biopharma INC. | $36.59 | 2020-2022 | |
| Siemens Medical Solutions USA, INC. | $29.15 | 2022 | |
| Allergan, INC. | $27.73 | 2020 | |
| Ambu INC. | $21.02 | 2020 | |
| Gilead Sciences, INC. | $20.37 | 2020 | |
| Qol Medical, LLC | $16.43 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.94 | 2021 | |
| Shionogi INC | $15.56 | 2019 | |
| Vivus LLC | $13.63 | 2021 | |
| Braintree Laboratories, INC. | $13.14 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.12 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$27,967.51 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Kedia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.